[設為首頁]  [加入收藏]

2012年美國干細胞治療應用大幅上升
2012-11-29 22:13:00   來源:   

Dramatic Rise in Stem Cell Therapy Use in 2012
Stem Cell Company Executives, Scientists, Investors and Physicians will present data Feb. 19,2013 at the 8th Annual New York Stem Cell Summit in New York City
PR Newswire ([url]http://s.tt/1uSNJ[/url])

PHILADELPHIA, Nov. 26, 2012 /PRNewswire/ -- RRY Publications LLC today announced that the use of stem cell therapies in 2012 significantly exceeded forecasts which were originally presented at the February 2012 New York Stem Cell Summit. Said Robin Young, stem cell industry analyst and host of the New York meeting: "The range and scope of stem cell therapeutic use in the United States grew much faster than we'd forecasted earlier this year. Virtually all of the increases we're seeing are for adult stem cell therapies and, in particular, the use by physicians of both allograft and autologous stem cell products. It would not be an exaggeration to call this unexpected and remarkable growth."
Mr. Young's revised forecast of stem cell commercialization revenues for 2013-2020 will be presented at the February meeting in New York.
The companies, scientists and physicians that are at the forefront of this remarkable increase in stem cell therapeutic use will be presenting at the 8th Annual New York Stem Cell Summit. Listed below is the preliminary lineup of presenters for the 8th Annual Stem Cell Summit.
The Stem Cell Summit, an intensive one-day event, allows attendees to learn about the latest developments in the stem cell marketplace, evaluate the groundbreaking stem cell products physicians are using today, and discover the growing market potential in terms of revenues. For 2013, the Summit will feature 30+ presenters, a research review and debate session, and a special track on expanding the range of stem cell therapies.
The 8th Annual Stem Cell Summit will take place on Feb. 19, 2013, at Bridgewaters in the heart of New York City's historic South Street Seaport. The preliminary roster of companies featured will include representatives from 2012 presenters and new 2013 presenters.

Aastrom Biosciences, Inc.
Advanced Cell Technology
Aldagen, Inc.
AllCells, LLC.
Aruna Biomedical, Inc.
Athersys, Inc.
Bioheart Inc.
BioLife Solutions
BioTime Inc./Embryome Sciences, Inc.
Brainstorm Cell Therapeutics
Case Western Reserve University
CellCyte Genetics Corp.
Celgene Corporation
Celtigen Therapeutics
Cord Blood America, Inc. (CBAI.OB)
Core Dynamics Ltd.
Cytori Therapeutics, Inc.
Gamida Cell Ltd.
Garnet BioTherapeutics, Inc.
Histogen Inc
INCELL Corporation LLC
International Stem Cell Corporation
Lifenet Health
Lonza Group Ltd. 
Medistem Inc.
Mesoblast Limited
MultiCell Technologies [MCET]
Neostem, Inc.
Neuralstem
Opexa Therapeutics, Inc.
Osiris Therapeutics, Inc.
Parcell Labs
Pathfinder Cell Therapy
Pervasis Therapeutics, Inc.
Pluristem Therapeutics, Inc.
Prochon Biotech, Ltd.
Progenitor Cell Therapy, LLC
Stem Cell Innovations
Stem Cell Therapeutics (SCTPF)
StemCells Inc.
TiGenix NV
Tissue Genesis, Inc.
TxCell
Vet-Stem, Inc.
ViaCyte
WuXi AppTec

In addition to the company and product overviews, Robin Young, president of RRY Publications and the organizer of the annual Stem Cell Summit, will deliver his updated 10-year market forecast for the industry.

相關熱詞搜索:2012年 美國 干細胞

上一篇:東亞在干細胞創新研究中所面臨的獨特機遇和挑戰
下一篇:日本宣布選定6家機構進行iPS細胞長期保存研究

分享到: 收藏